The applications of bone marrow transplantation have been limited by the serious morbidity and mortality associated with the procedure. In this article we discuss improvements in our understanding of the immunobiology of marrow transplantation. We also describe how the availability of recombinant growth factors for the haemopoietic and immune systems and the introduction of immunomodulatory monoclonal antibodies are beginning to make a major impact on the practice and outcome of the procedure.
|Original language||English (US)|
|Number of pages||6|
|Journal||British Journal of Hospital Medicine|
|State||Published - Mar 1989|
ASJC Scopus subject areas
- Reviews and References, Medical